Certain clinical prognostic factors (such as age, gender, immunohistochemical subtypes, infiltration site, tumor size, EOR, BMI, ADC value, ECOG score, etc.)and biological prognostic factors (such as ki-67, IDH1, IDH2, MGMT, etc.)have been shown to predict the risk of recurrence in glioma patients [115–118]. This evidence concerns the gene MGMT and glioma.